Call to arrange a consultation
+1 416 777 0888

Novartis Pharmaceuticals Canada Inc. et al. v. Pharmascience Inc.

2022
T-2582-22
Pending
New PM(NOC) Regulations

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan)

Counsel to: 
Pharmascience Inc.
here.